Dementia

Lithium: what’s its history and where do we still need more information?

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

"Dementia is a mental health condition that can make or break families. Remember that behind the difficult behavior is your loved one."

What's the latest in dementia?

"To be sure, we are still in the nascent stages of developing treatments. However, our armamentarium is steadily growing."

From the cross-cultural dimensions of psychosis to the economic burden of schizophrenia, here are highlights from the week in Psychiatric Times.

Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.

From the relationship between psychotic disorders and dementia risk to the major differences between bipolar I and bipolar II, here are highlights from the week in Psychiatric Times.

Individuals with a psychotic disorder are 2.5 times more likely than those without one to develop dementia.

According to new research, treating depression in older adults could decrease risk of dementia by 51%.

From herbal medicine for psychiatrists to the psychiatric implications of the Parkland School massing shooting, here are highlights from the week in Psychiatric Times.

A reminder to cherish your parents and the older adults in your life.

Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.

If we don't find a cure or adequate treatments, the number of individuals impacted by dementia could skyrocket to nearly 14 or 15 million Americans by 2050.

Top-line data for study is expected in late 2022, early 2023.

How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?

Research also finds surprising results in patients with bipolar affective disorder.

Decades of efforts to find effective medical treatments for dementia and Alzheimers disease have largely failed. Would a public health approach be more effective?

What advice can clinicians give patients to lower their overall risk for neurodegenerative diseases?

Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?

Sleep problems are understudied, underdiagnosed, and undertreated.

Gene expressions in microglia cells may explain why some of them are ineffective and allow dementia to progress.

CRL cites lack of substantial evidence of efficacy needed for approval.

Aducanumab is named 1 of the 5 “Drugs to Watch” for 2021.

About 2.4 million people in the US experience dementia related psychosis, yet only half ever receive a diagnosis.